Baseline Demographics and Disease Characteristics from ORATORIO, a Phase III Trial Evaluating Ocrelizumab in Patients with Primary Progressive Multiple Sclerosis

被引：0

作者：

Montalban, X. ^{[1
]}

Hemmer, B. ^{[2
]}

Rammohan, K. ^{[3
]}

Giovannoni, G. ^{[4
]}

de Seze, J. ^{[5
]}

Bar-Or, A. ^{[6
]}

Arnold, D. ^{[6
]}

Sauter, A. ^{[7
]}

Leppert, D. ^{[8
]}

Chin, P. ^{[9
]}

Garren, H. ^{[8
]}

Messier, M. ^{[8
]}

Wolinski, J. ^{[10
]}

Kakarieka, A. ^{[8
]}

Masterman, D. ^{[9
]}

机构：

[1] Vall dHebron Univ Hosp, Dept Neurol Neuroimmunol, Barcelona, Spain

[2] Tech Univ Munich, Neurol, D-80290 Munich, Germany

[3] Univ Miami Hlth Syst, MS Ctr Excellence, Miami, FL USA

[4] Barts & London Queen Marys Sch Med & Dent, Neurosci, London, England

[5] Univ Hosp Strasbourg, Neurol, Strasbourg, France

[6] McGill Univ, Montreal Neurol Inst & Hosp, Montreal, PQ, Canada

[7] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland

[8] F Hoffmann La Roche & Co Ltd, Neurosci, CH-4002 Basel, Switzerland

[9] Genentech Roche, Neurosci, San Francisco, CA USA

[10] Univ Texas Houston, Sch Med, Neurosci, Houston, TX USA

来源：

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

F3049

引用

页码：706 / 706

页数：1